Literature DB >> 30945963

The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis.

Olatunji O Adetokunboh1,2, Ajibola Awotiwon3, Duduzile Ndwandwe1, Olalekan A Uthman1,2,4, Charles S Wiysonge1,2,5.   

Abstract

There are knowledge gaps regarding evidence-based research on the burden of vaccine-preventable diseases among human immunodeficiency virus (HIV)-infected and HIV-exposed children aged <18 years in sub-Saharan Africa. It is therefore essential to determine the trend and burden of vaccine-preventable diseases. We completed a systematic review and meta-analysis to identify the incidence, prevalence and case-fatality rates (CFR) attributed to various vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa. The trends in the prevalence of vaccine-preventable diseases among HIV-infected and HIV-exposed children were also determined. Nine studies on tuberculosis (TB) were pooled to give an overall incidence rate estimate of 60 (95% confidence interval [CI] 30-70) per 1,000 child-years. The incidence of pneumococcal infections varied between 109-1509 per 100,000 while pertussis was between 2.9 and 3.7 per 1000 child-year. Twenty-two TB prevalence studies reported an estimated prevalence of 16%. Fifteen prevalence studies on hepatitis B infection were pooled together with an estimated prevalence of 5%. The pooled prevalence for pneumococcal infections was 2% while rotavirus diarrhoea reported a prevalence of 13%. Twenty-nine studies on TB were pooled to give an overall CFR estimate of 17% while pneumococcal infections in HIV-infected and exposed children were pooled together with a resultant rate of 15%. Some of the vaccine-preventable diseases still have high incidences, prevalence and CFR among HIV-infected and HIV-exposed children. There is also a dearth of research data on the burden of several vaccine-preventable diseases among HIV-infected and exposed children and a need for more studies in this area.

Entities:  

Keywords:  HIV; burden; sub-Saharan Africa; vaccine-preventable diseases

Mesh:

Year:  2019        PMID: 30945963      PMCID: PMC6930054          DOI: 10.1080/21645515.2019.1599676

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  89 in total

1.  Performance of the QuantiFERON-TB gold interferon gamma release assay among HIV-infected children in Botswana.

Authors:  Andrea T Cruz; Marape Marape; Edward A Graviss; Jeffrey R Starke
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-08-22

2.  Incidence of tuberculosis meningitis in a high HIV prevalence setting: time-series analysis from 2006 to 2011.

Authors:  S Chaya; Z Dangor; F Solomon; S A Nzenze; A Izu; S A Madhi
Journal:  Int J Tuberc Lung Dis       Date:  2016-11       Impact factor: 2.373

3.  Outcomes of integrated treatment for tuberculosis and HIV in children at the primary health care level.

Authors:  M R Patel; M Yotebieng; F Behets; K Vanden Driessche; M Nana; A Van Rie
Journal:  Int J Tuberc Lung Dis       Date:  2013-07-03       Impact factor: 2.373

4.  Treatment Outcomes of Children With HIV Infection and Drug-resistant TB in Three Provinces in South Africa, 2005-2008.

Authors:  Eric W Hall; Sapna B Morris; Brittany K Moore; Linda Erasmus; Ronel Odendaal; Heather Menzies; Martie van der Walt; Sarah E Smith
Journal:  Pediatr Infect Dis J       Date:  2017-12       Impact factor: 2.129

5.  Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment.

Authors:  Marcel Yotebieng; Annelies Van Rie; Harry Moultrie; Stephen R Cole; Adaora Adimora; Frieda Behets; Tammy Meyers
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

6.  Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa.

Authors:  Nafiisah Chotun; Etienne Nel; Mark F Cotton; Wolfgang Preiser; Monique I Andersson
Journal:  Vaccine       Date:  2015-07-09       Impact factor: 3.641

7.  Low vaccine coverage among children born to HIV infected women in Niamey, Niger.

Authors:  Hyppolite Kuekou Tchidjou; Maria Fenicia Vescio; Martin Sanou Sobze; Animata Souleyman; Paola Stefanelli; Adalbert Mbabia; Ide Moussa; Bruno Gentile; Vittorio Colizzi; Giovanni Rezza
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

8.  Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program.

Authors:  Marta C Nunes; Anne von Gottberg; Linda de Gouveia; Cheryl Cohen; Locadiah Kuwanda; Alan S Karstaedt; Keith P Klugman; Shabir A Madhi
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

9.  Gaps in the Child Tuberculosis Care Cascade in 32 Rural Communities in Uganda and Kenya.

Authors:  Florence Mwangwa; Gabriel Chamie; Dalsone Kwarisiima; James Ayieko; Asiphas Owaraganise; Theodore D Ruel; Albert Plenty; Khai Hoan Tram; Tamara D Clark; Craig R Cohen; Elizabeth A Bukusi; Maya Petersen; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Carina Marquez
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-12

10.  Routine vaccination coverage in low- and middle-income countries: further arguments for accelerating support to child vaccination services.

Authors:  Wenjing Tao; Max Petzold; Birger C Forsberg
Journal:  Glob Health Action       Date:  2013-04-30       Impact factor: 2.640

View more
  1 in total

1.  Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium.

Authors:  Sophie Desmonde; Anne M Neilan; Beverly Musick; Gabriela Patten; Kulkanya Chokephaibulkit; Andrew Edmonds; Stephany N Duda; Karen Malateste; Kara Wools-Kaloustian; Andrea L Ciaranello; Mary-Ann Davies; Valériane Leroy
Journal:  J Int AIDS Soc       Date:  2020-10       Impact factor: 5.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.